Stocks Up as Bullar...
Health Care: Drugs
Galena Biopharma Inc (GALE: NASDAQ)
$2.50 0.04 | 1.42%
05/21/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 32.81M | 11.43M | 6.89M | 5.68M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 36.12M | 11.81M | 7.04M | 5.80M |
| Property, Plant & Equipment, Gross | 48.00K | 1.05M | 910.00K | 752.00K |
| Accumulated Depreciation & Depletion | 19.00K | 657.00K | 491.00K | 320.00K |
| Property, Plant & Equipment, Net | 29.00K | 393.00K | 419.00K | 432.00K |
| Intangibles | 12.86M | 12.86M | 0.00 | 0.00 |
| Other Non-Current Assets | 74.00K | 3.00K | 16.00K | 16.00K |
| Total Non-Current Assets | 18.86M | 19.16M | 435.00K | 448.00K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 54.99M | 30.97M | 7.48M | 6.25M |
| Accounts Payable | 1.98M | 2.16M | 724.00K | 625.00K |
| Short Term Debt | 6.00K | 35.00K | 51.00K | 52.00K |
| Other Current Liabilities | 11.90M | 5.53M | 3.14M | 3.72M |
| Total Current Liabilities | 15.92M | 11.20M | 5.03M | 5.48M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 5.05M | 5.05M | 0.00 | 0.00 |
| Other Non-Current Liabilities | 6.21M | 4.57M | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 11.31M | 9.65M | 20.00K | 36.00K |
| Total Liabilities | 27.23M | 20.86M | 5.05M | 5.51M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 27.76M | 10.11M | 2.43M | 741.00K |
| Common Par | 8.00K | 5.00K | 2.00K | 2.00K |
| Additional Paid In Capital | 132.17M | 81.18M | 62.02M | 44.49M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -102.20M | -67.23M | -55.74M | -43.75M |
| Treasury Stock | -3.85M | -3.85M | -3.85M | 0.00 |
| Other Equity Adjustments | 1.63M | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 27.76M | 10.11M | 2.43M | 741.00K |
| Total Equity | 27.76M | 10.11M | 2.43M | 741.00K |
| Total Liabilities & Stock Equity | 54.99M | 30.97M | 7.48M | 6.25M |
| Total Common Shares Outstanding | 82.92M | 47.14M | 18.37M | 16.21M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 675.00K | 675.00K | 675.00K | 0.00 |
| Basic Weighted Shares Outstanding | 62.48M | 36.33M | 17.88M | 14.80M |
| Diluted Weighted Shares Outstanding | 62.48M | 36.33M | 17.88M | 14.80M |
| Number of Employees | 12 | 29 | 32 | 27 |
| Number of Part-Time Employees | 0 | 0 | 0 | 1 |
Portfolios with GALE
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserMy Portfolio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
Latest GALE Headlines from TheStreet
- Galena Biopharma To Present At The 2013 BIO International Convention 04.16.13 | 07:04 am
- Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy 04.12.13 | 06:04 am
- 4 Biotech Stocks Under $10 Making Big Moves 04.09.13 | 02:04 pm
- Galena Biopharma To Present At The 20th Annual Future Leaders In The Biotech Industry Conference 03.29.13 | 07:03 am
- 4 Stocks Under $10 Making Big Moves 03.26.13 | 02:03 pm
- Galena Biopharma Acquires Abstral(R) (fentanyl) Sublingual Tablets In U.S., A Novel, Best-in-Class Treatment Approved For Breakthrough Cancer Pain 03.18.13 | 03:03 am
- Galena Biopharma Receives 2013 Global Frost & Sullivan Award For New Product Innovation For NeuVax(TM) 03.14.13 | 07:03 am
- Galena Biopharma Reports Year-End 2012 Financial Results 03.12.13 | 04:03 pm
- Galena Biopharma To Present At The 25th Annual ROTH Conference 03.11.13 | 07:03 am
- Galena Biopharma To Present At The 7th Annual Bio-Europe International Partnering Conference 03.04.13 | 07:03 am
Press Releases for GALE
- Frost & Sullivan Applauds Galena Biopharma For Its Breakthrough Breast Cancer Vaccine, NeuVaxâ¿¢ - PR Newswire 03.12.13 | 07:03 am
- Galena Biopharma, Inc. Investor Presentation Now Available For On-demand Viewing At RetailInvestorConferences.com - PR Newswire 06.12.12 | 09:06 am
- Galena Biopharma, Inc. To Webcast, Live, At RetailInvestorConferences.com On June 7th - PR Newswire 06.06.12 | 09:06 am
- RXi Pharmaceuticals’ Common Stock To Commence Trading Under The Symbol “RXII” - Business Wire 05.10.12 | 06:05 am
Partner Headlines for GALE
- Galena Biopharma: Will Developments Continue In 2013? - Seeking Alpha 04.03.13 | 09:04 am
- What Makes For A Market Leading Return In Biotechnology? - Seeking Alpha 01.22.13 | 09:01 am
- Galena Pulls Back While Analysts Rush To Its Defense - Seeking Alpha 12.17.12 | 08:12 am
- Biotech Under The Electron Microscope: What's In The Pipeline And Lessons To Be Learned - Seeking Alpha 12.16.12 | 08:12 am
- Morning Market Movers - Benzinga 12.04.12 | 09:12 am
- UPDATE: Aegis Capital Corp. Initiates Coverage on Galena Biopharma with Buy Rating, $6 PT - Benzinga 11.28.12 | 09:11 am
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- Reassessing & Continuing To Monitor Portfolios For Success - Seeking Alpha 07.30.12 | 09:07 am
- Are Galena Biopharma's Largest Shareholders Giddy About Their Drug Trial Results? - Wall St. Cheat Sheet 06.21.12 | 11:06 am
- Galena Biopharma Announces Public Offering of Common Stock - Benzinga 04.04.12 | 04:04 pm
